Impact of gender on statin efficacy

Current Medical Research and Opinion

Volumn 23, Issue 3, 2007, Pages 565-574

  Dale, Krista M ^a,c   Coleman, Craig I ^a,c   Shah, Sachin A ^a,c   Patel, Aarti A ^a,c   Kluger, Jeffrey ^b,c   White, C Michael ^a,c,d  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c HARTFORD HOSPITAL   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Death; Gender; HMG CO A reductase inhibitor; Myocardial infarction; Statin; Stroke

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; HEART INFARCTION; HUMAN; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; REVASCULARIZATION; RISK ASSESSMENT; SEX DIFFERENCE; STROKE; SYSTEMATIC REVIEW; UNSTABLE ANGINA PECTORIS;

AGE DISTRIBUTION; AGED; CARDIOVASCULAR DISEASES; COMORBIDITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INCIDENCE; MALE; MIDDLE AGED; ODDS RATIO; PRAVASTATIN; PROBABILITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; REGRESSION ANALYSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SIMVASTATIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33947398335     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X167516     Document Type: Article

References (25)

1. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-92
2. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin- converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003;41:1529-38
3. Villar IC, Francis S, Web A, et al. Novel aspects of endothelium- dependent regulation of vascular tone. Kidney Int 2006;70: 840-53
4. Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10:101-29
5. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50: 1088-101
6. Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34
7. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48
8. The ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007
9. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Eng J Med 1996;335:1001-9
10. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Eng J Med 1998;339:1349-57
11. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002;360;1623-30
12. Bestehorn HR, Rensing UF, Roskamm H, et al. The effect of simvastatin on progression of coronary artery disease. The Multicenter Coronary Intervention Study (CIS). Eur Heart J 1997;18:226-34
13. Pedersen TR, Kjekshys J, Berg K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-90
14. Heart Protection Study Collaborative Group. MCR/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22
15. Sever PS, Poulter NR, Wedel H, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average of lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet 2003;361:1149-58
16. Waters D, Higginson L, Gladstone P, et al. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women: A Canadian coronary atherosclerosis intervention trial (CCAIT) substudy. Circulation 1995;92:2402-10
17. Downs JF, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22
18. Serruys PWJ, deFeyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287:3215-22
19. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the cholesterol program goal versus 'usual' care in secondary coronary heart disease prevention: The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:220-8
20. Pitt B, Mancini GB, Ellis SG, et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J Am Coll Cardiol 1995;26:1133-9
21. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Eng J Med 1995;333:1301-7
22. Clearfield M, Downs JR, Weis S, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/ TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. J Womens Health Gend Based Med 2001;10:971-81
23. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049-57
24. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The metroprolol CR/XL randomized intervention trial in congestive heart failure (MERIT HF). JAMA 2000;283:1295-302
25. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67